Hot Casino Stocks To Watch For 2019

tags:TCON,NGVC,GSBD,AROC,EME,SNDX,

Check out the companies making headlines before the bell:

Deutsche Bank — Deutsche Bank and rival German bank Commerzbank confirmed that they are in merger talks, although both said a deal was not assured.

Caesars Entertainment — Caesars and Eldorado Resorts are in the early stages of exploring a merger, according to Reuters. Investor Carl Icahn has been pushing Caesars to explore a sale after taking a stake in the casino operator and putting three nominees on the board of directors.

Boeing — The Department of Transportation and federal prosecutors are scrutinizing the development of Boeing's 737 MAX jets, according to The Wall Street Journal. The 737 MAX 8 was involved in last week's Ethiopian Airlines crash as well as a Lion Air crash in Indonesia a few months ago.

Hot Casino Stocks To Watch For 2019: TRACON Pharmaceuticals, Inc.(TCON)

Advisors' Opinion:

• [By Stephan Byrd]

  TRACON Pharmaceuticals Inc (NASDAQ:TCON) fell 12.3% during trading on Wednesday . The company traded as low as $1.23 and last traded at $1.21. 896,880 shares changed hands during trading, an increase of 112% from the average session volume of 422,831 shares. The stock had previously closed at $1.38.

• [By Shane Hupp]

  Get a free copy of the Zacks research report on TRACON Pharmaceuticals (TCON)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Casino Stocks To Watch For 2019: Natural Grocers by Vitamin Cottage, Inc.(NGVC)

Advisors' Opinion:

• [By Max Byerly]

  Get a free copy of the Zacks research report on Natural Grocers by Vitamin Cottage (NGVC)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Logan Wallace]

  Ahold Delhaize (OTCMKTS: ADRNY) and Vitamin Cottage Natural Grocers (NYSE:NGVC) are both consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

• [By Motley Fool Transcribers]

  Natural Grocers by Vitamin Cottage Inc  (NYSE:NGVC)Q1 2019 Earnings Conference CallFeb. 07, 2019, 4:30 p.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Lisa Levin] Gainers Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares rose 35.8 percent to $3.00. Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares surged 32 percent to $8.94 after reporting upbeat Q1 earnings. Carbon Black, Inc. (NASDAQ: CBLK) gained 29.6 percent to $24.62. Carbon Black priced its IPO at $19 per share. California Resources Corporation (NYSE: CRC) shares rose 26.8 percent to $32.70 following upbeat Q1 earnings. Pandora Media, Inc. (NYSE: P) gained 25 percent to $7.185 after reporting strong quarterly results. Medifast, Inc. (NYSE: MED) shares climbed 23.7 percent to $122.87 after the company reported strong Q1 results and raised its FY18 guidance. Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.2 percent to $8.4999 after reporting Q2 results. Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) gained 22.2 percent to $41.27 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban. Shake Shack Inc (NYSE: SHAK) rose 22.2 percent to $57.955 after the company reported upbeat results for its first quarter and raised its FY18 guidance. Atomera Incorporated (NASDAQ: ATOM) jumped 19.7 percent to $6.12 after reporting Q1 results. Super Micro Computer, Inc. (NASDAQ: SMCI) rose 16.4 percent to $21.00 after reporting strong preliminary results for the third quarter. Titan International, Inc. (NYSE: TWI) shares rose 16.4 percent to $12.21 following Q1 earnings. Integer Holdings Corporation (NYSE: ITGR) shares gained 14.9 percent to $63.75 following Q1 results. Control4 Corporation (NASDAQ: CTRL) shares climbed 14.5 percent to $23.98 folloiwng strong Q1 results. B&G Foods, Inc. (NYSE: BGS) climbed 12.6 percent to $25.40 after reporting Q1 earnings. HMS Holdings Corp (NASDAQ: HMSY) shares gained 10 percent to $19.59 after reporting upbeat quarterly earnings. Viavi Solutions Inc. (NASDAQ: VIAV) rose 7 percent to $10.09 following Q3 r
• [By Joseph Griffin]

  ValuEngine upgraded shares of Natural Grocers by Vitamin Cottage (NYSE:NGVC) from a buy rating to a strong-buy rating in a research note released on Tuesday.

Hot Casino Stocks To Watch For 2019: Goldman Sachs BDC, Inc.(GSBD)

Advisors' Opinion:

• [By Logan Wallace]

  Tortoise Energy Infrastructure (NYSE: GSBD) and Goldman Sachs BDC (NYSE:GSBD) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

• [By Max Byerly]

  News headlines about Goldman Sachs BDC (NYSE:GSBD) have trended somewhat positive on Thursday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Goldman Sachs BDC earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news coverage about the financial services provider an impact score of 46.3769468004989 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

• [By Max Byerly]

  Stifel Financial Corp trimmed its position in Goldman Sachs BDC Inc (NYSE:GSBD) by 48.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,440 shares of the financial services provider’s stock after selling 11,736 shares during the quarter. Stifel Financial Corp’s holdings in Goldman Sachs BDC were worth $238,000 at the end of the most recent reporting period.

• [By Shane Hupp]

  Goldman Sachs BDC Inc (NYSE:GSBD) has been given a consensus rating of “Hold” by the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $22.50.

Hot Casino Stocks To Watch For 2019: Archrock, Inc.(AROC)

Advisors' Opinion:

• [By Motley Fool Transcribing]

  Archrock (NYSE:AROC) Q4 2018 Earnings Conference CallFeb. 20, 2019 11:00 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Ethan Ryder]

  News stories about Archrock (NYSE:AROC) have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Archrock earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave headlines about the energy company an impact score of 47.3449329112104 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

• [By Ethan Ryder]

  Archrock (NYSE:AROC) posted its quarterly earnings data on Tuesday. The energy company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.02, Briefing.com reports. The firm had revenue of $233.20 million during the quarter, compared to analysts’ expectations of $232.15 million. Archrock had a net margin of 6.32% and a return on equity of 2.49%. The business’s revenue was up 11.6% compared to the same quarter last year.

• [By Tyler Crowe]

  After years of struggling with the precipitous decline in oil prices and an onerous debt load, management at Archrock (NYSE:AROC) decided to bite the bullet and buy out its subsidiary master limited partnership Archrock Partners. According to management, the deal would free up some cash and lower its cost of capital. The combination of these two things would make it easier to grow the business and take advantage of the monumental growth of natural gas production in the U.S.

• [By Tyler Crowe]

  Oil and gas infrastructure specialist Archrock (NYSE:AROC) and its former subsidiary Archrock Partners were once a textbook case of an overaggressive business that got rocked by crashing oil and gas prices. The company bet heavily on the need for compression horsepower to force oil and gas from wells to pipelines, and took on considerable leverage to do so. When demand dried up from lower production volumes, Archrock was stuck with a fleet of inactive compression equipment and a massive debt load.

Hot Casino Stocks To Watch For 2019: EMCOR Group, Inc.(EME)

Advisors' Opinion:

• [By Shane Hupp]

  Get a free copy of the Zacks research report on Emcor Group (EME)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  Shares of Emcor Group Inc (NYSE:EME) have been assigned a consensus rating of “Hold” from the six analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $87.00.

• [By Ethan Ryder]

  Emcor Group Inc (NYSE:EME) declared a quarterly dividend on Monday, July 9th, RTT News reports. Stockholders of record on Friday, July 20th will be given a dividend of 0.08 per share by the construction company on Tuesday, July 31st. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.41%.

Hot Casino Stocks To Watch For 2019: Syndax Pharmaceuticals, Inc. (SNDX)

Advisors' Opinion:

• [By Lisa Levin]

  Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was down, falling around 22 percent to $8.634 after the company issued updated results from Phase 2 ENCORE trial of entinostat in combo with KEYTRUDA.

• [By Logan Wallace]

  Get a free copy of the Zacks research report on Syndax Pharmaceuticals (SNDX)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Logan Wallace]

  Several institutional investors have recently bought and sold shares of the company. BVF Inc. IL acquired a new position in shares of Syndax Pharmaceuticals during the 4th quarter worth about $28,326,000. Millennium Management LLC grew its position in shares of Syndax Pharmaceuticals by 18.9% during the 4th quarter. Millennium Management LLC now owns 516,500 shares of the company’s stock worth $4,525,000 after buying an additional 82,256 shares during the period. Geode Capital Management LLC grew its position in shares of Syndax Pharmaceuticals by 17.4% during the 4th quarter. Geode Capital Management LLC now owns 153,483 shares of the company’s stock worth $1,344,000 after buying an additional 22,803 shares during the period. Crestline Management LP grew its position in shares of Syndax Pharmaceuticals by 55.3% during the 4th quarter. Crestline Management LP now owns 83,139 shares of the company’s stock worth $728,000 after buying an additional 29,607 shares during the period. Finally, State Street Corp grew its position in shares of Syndax Pharmaceuticals by 32.8% during the 2nd quarter. State Street Corp now owns 81,327 shares of the company’s stock worth $1,137,000 after buying an additional 20,106 shares during the period. Institutional investors own 69.55% of the company’s stock.

  TRADEMARK VIOLATION WARNING: “Syndax Pharmaceuticals (SNDX) Rating Lowered to D at TheStreet” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3364448/syndax-pharmaceuticals-sndx-rating-lowered-to-d-at-thestreet.html.

  About Syndax Pharmaceuticals

• [By Jon C. Ogg]

  Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) was started with a Buy rating and assigned a $30 price target at H.C. Wainwright on July 12. This is a small $175 million market cap company at the time of the call, but the price target in this call was about 300% higher than the $7.10 closing price. Syndax has a 52-week range of $6.61 to $15.20, and its most recent closing price was $7.49. The cancer pipeline has been the focus for such large upside here, and at one point one analyst was pointing to Syndax rallying to as high as $40.

• [By ]

  Syndax (SNDX) is developing entinostat, a Class I HDAC inhibitor, for the treatment of solid tumors. Shares popped recently following the release of Syndax's first quarter earnings results, but a bigger catalyst on the horizon is the upcoming ASCO oncology conference in June. Syndax is due to present updated data from the ENCORE-601 Phase 2 trial in melanoma and lung cancer.